Literature DB >> 31657732

Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Louisa Degenhardt1, Jason Grebely2, Jack Stone3, Matthew Hickman3, Peter Vickerman3, Brandon D L Marshall4, Julie Bruneau5, Frederick L Altice6, Graeme Henderson7, Afarin Rahimi-Movaghar8, Sarah Larney9.   

Abstract

We summarise the evidence for medicinal uses of opioids, harms related to the extramedical use of, and dependence on, these drugs, and a wide range of interventions used to address these harms. The Global Burden of Diseases, Injuries, and Risk Factors Study estimated that in 2017, 40·5 million people were dependent on opioids (95% uncertainty interval 34·3-47·9 million) and 109 500 people (105 800-113 600) died from opioid overdose. Opioid agonist treatment (OAT) can be highly effective in reducing illicit opioid use and improving multiple health and social outcomes-eg, by reducing overall mortality and key causes of death, including overdose, suicide, HIV, hepatitis C virus, and other injuries. Mathematical modelling suggests that scaling up the use of OAT and retaining people in treatment, including in prison, could avert a median of 7·7% of deaths in Kentucky, 10·7% in Kiev, and 25·9% in Tehran over 20 years (compared with no OAT), with the greater effects in Tehran and Kiev being due to reductions in HIV mortality, given the higher prevalence of HIV among people who inject drugs in those settings. Other interventions have varied evidence for effectiveness and patient acceptability, and typically affect a narrower set of outcomes than OAT does. Other effective interventions focus on preventing harm related to opioids. Despite strong evidence for the effectiveness of a range of interventions to improve the health and wellbeing of people who are dependent on opioids, coverage is low, even in high-income countries. Treatment quality might be less than desirable, and considerable harm might be caused to individuals, society, and the economy by the criminalisation of extramedical opioid use and dependence. Alternative policy frameworks are recommended that adopt an approach based on human rights and public health, do not make drug use a criminal behaviour, and seek to reduce drug-related harm at the population level.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31657732      PMCID: PMC7068135          DOI: 10.1016/S0140-6736(19)32229-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  174 in total

1.  Knowledge of HIV serostatus and preventive behaviour among European injecting drug users: second study. European Community Study Group on HIV in Injecting Drug Users.

Authors:  M G Schlumberger; J C Desenclos; G Papaevangelou; S C Richardson; R Ancelle-Park
Journal:  Eur J Epidemiol       Date:  1999-03       Impact factor: 8.082

2.  Abuse of prescription drugs and the risk of addiction.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2006-03-23       Impact factor: 4.492

Review 3.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

4.  Fentanyl in the US heroin supply: A rapidly changing risk environment.

Authors:  Daniel Ciccarone
Journal:  Int J Drug Policy       Date:  2017-07-20

Review 5.  Supervised injection services: what has been demonstrated? A systematic literature review.

Authors:  Chloé Potier; Vincent Laprévote; Françoise Dubois-Arber; Olivier Cottencin; Benjamin Rolland
Journal:  Drug Alcohol Depend       Date:  2014-10-23       Impact factor: 4.492

6.  Racial/Ethnic differences in factors that place adolescents at risk for prescription opioid misuse.

Authors:  Jason A Ford; Khary K Rigg
Journal:  Prev Sci       Date:  2015-07

7.  Medications For Addiction Treatment: Changing Language to Improve Care.

Authors:  Sarah E Wakeman
Journal:  J Addict Med       Date:  2017 Jan/Feb       Impact factor: 3.702

8.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05

9.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

Review 10.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.

Authors:  Sarah Larney; Amy Peacock; Janni Leung; Samantha Colledge; Matthew Hickman; Peter Vickerman; Jason Grebely; Kostyantyn V Dumchev; Paul Griffiths; Lindsey Hines; Evan B Cunningham; Richard P Mattick; Michael Lynskey; John Marsden; John Strang; Louisa Degenhardt
Journal:  Lancet Glob Health       Date:  2017-10-23       Impact factor: 26.763

View more
  111 in total

1.  Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.

Authors:  Heather Valerio; Maryam Alavi; David Silk; Carla Treloar; Marianne Martinello; Andrew Milat; Adrian Dunlop; Jo Holden; Charles Henderson; Janaki Amin; Phillip Read; Philippa Marks; Louisa Degenhardt; Jeremy Hayllar; David Reid; Carla Gorton; Thao Lam; Gregory J Dore; Jason Grebely
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

2.  Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia.

Authors:  Sarah Larney; Nicola Jones; David A Fiellin; Suzanne Nielsen; Matthew Hickman; Timothy Dobbins; Thomas Murphy; Robert Ali; Louisa Degenhardt
Journal:  Int J Epidemiol       Date:  2021-01-23       Impact factor: 7.196

3.  Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.

Authors:  Jason Grebely; Lucy Tran; Louisa Degenhardt; Alexander Dowell-Day; Thomas Santo; Sarah Larney; Matthew Hickman; Peter Vickerman; Clare French; Kerryn Butler; Daisy Gibbs; Heather Valerio; Phillip Read; Gregory J Dore; Behzad Hajarizadeh
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

Review 4.  Opioid use disorder.

Authors:  John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh
Journal:  Nat Rev Dis Primers       Date:  2020-01-09       Impact factor: 52.329

5.  Impact of workplace injury on opioid dependence, abuse, illicit use and overdose: a 36-month retrospective study of insurance claims.

Authors:  Abay Asfaw; Leslie I Boden
Journal:  Occup Environ Med       Date:  2020-04-24       Impact factor: 4.402

Review 6.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

7.  The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.

Authors:  Scott O Farnum; Iuliia Makarenko; Lynn Madden; Alyona Mazhnaya; Ruthanne Marcus; Tanya Prokhorova; Martha J Bojko; Julia Rozanova; Sergii Dvoriak; Zahedsul Islam; Frederick L Altice
Journal:  Addiction       Date:  2020-08-09       Impact factor: 6.526

8.  Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes.

Authors:  Richard Sherva; Congcong Zhu; Leah Wetherill; Howard J Edenberg; Emma Johnson; Louisa Degenhardt; Arpana Agrawal; Nicholas G Martin; Elliot Nelson; Henry R Kranzler; Joel Gelernter; Lindsay A Farrer
Journal:  Explor Med       Date:  2021-02-28

Review 9.  Responding to global stimulant use: challenges and opportunities.

Authors:  Michael Farrell; Natasha K Martin; Emily Stockings; Annick Bórquez; Javier A Cepeda; Louisa Degenhardt; Robert Ali; Lucy Thi Tran; Jürgen Rehm; Marta Torrens; Steve Shoptaw; Rebecca McKetin
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

Review 10.  Soft Tissue, Bone, and Joint Infections in People Who Inject Drugs.

Authors:  Carlos S Saldana; Darshali A Vyas; Alysse G Wurcel
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.